Severe acute respiratory syndrome coronavirus 2 Spike protein receptor-binding domain (Omicron variant) (SARS-CoV-2 Spike RBD (Omicron))

The SARS-CoV-2 Spike receptor-binding domain (RBD) of the Omicron variant is a critical component of the viral spike glycoprotein that mediates the virus's entry into host cells. It specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, initiating the fusion process between the viral and host cell membranes [5, 11]. The Omicron variant (B.1.1.529) is characterized by an unusually high number of mutations within the RBD, such as N501Y, T478K, and E484A, which significantly enhance its binding affinity for ACE2 and facilitate immune evasion [1, 13, 15]. These mutations allow the virus to bypass neutralizing antibodies elicited by previous infections or early-generation vaccines, leading to increased transmissibility and breakthrough infections [10, 16]. Consequently, the Omicron RBD is a primary target for the development of updated vaccines and next-generation monoclonal antibodies [1, 5]. While many early therapeutic antibodies lost efficacy against this variant, newer agents like bebtelovimab were designed to target conserved epitopes within the domain [1, 7]. Understanding the structural dynamics of the Omicron RBD is essential for monitoring viral evolution and ensuring the continued effectiveness of COVID-19 countermeasures [18, 19].

Other names

SARS-CoV-2 S-RBD (Omicron)B.1.1.529 Spike RBDOmicron RBDomRBDSARS-CoV-2 Spike protein receptor-binding domain (Omicron variant)

Neutralization of viral entry by blocking the interaction between the viral receptor-binding domain and the host angiotensin-converting enzyme 2 (ACE2) receptor [1, 5, 10].